The Cheapest Way to Get Tirzepatide Legally in 2026

Tirzepatide is the active ingredient in two Eli Lilly brands: Mounjaro, approved for type 2 diabetes, and Zepbound, approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Same molecule, same manufacturer, same six strengths, two separate commercial programs and two very different prices.

Which brand you can be prescribed depends on your diagnosis. That is a clinical decision for a healthcare provider, not a shopping decision, and nothing below should be read as a suggestion to seek a diagnosis you do not have. What follows is a price map of the legal routes, ranked, with the catch attached to each.

The ranking, at a glance

Rank	Route	Monthly cost	Who it works for
1	Commercial insurance + Lilly savings card	As little as $25	Plan already covers Zepbound or Mounjaro
2	Medicare GLP-1 Bridge	$50 flat	Eligible Part D beneficiaries, KwikPen only
3	Medicaid in a covering state	$0 to $8	Medicaid enrollees, state-dependent
4	Lilly self-pay, Zepbound	$299 to $449 by dose	Anyone with an on-label prescription
5	Lilly self-pay, Mounjaro	From $499, same at every dose	Anyone with a type 2 diabetes prescription
6	Savings card, non-covered tier	$499	Commercial plan that excludes the drug
7	Compounded tirzepatide	About $179 to $549 advertised	Narrow and legally shrinking
—	Retail cash, no program	About $1,000 to $1,350	Nobody should end up here

1. Commercial insurance plus the Lilly savings card: as little as $25

If your commercial drug plan actually covers the drug, this is the cheapest route and nothing else comes close.

Zepbound. With commercial insurance that covers the Zepbound single-dose pen, the savings card can bring a fill to as little as $25 for a one-, two- or three-month prescription. Savings are capped at $100 per one-month fill and $1,300 per calendar year, across at most 13 fills (verified 2026-09-14 on zepbound.lilly.com/savings) [1][2]. This is a savings-card tier, not a self-pay price.

Mounjaro. With commercial insurance that covers Mounjaro and a type 2 diabetes prescription, the card can also reach as little as $25, with higher caps: $150 per month and $1,950 per calendar year, up to 13 fills [3].

The catch. Three of them. First, coverage is rare: GoodRx’s MMIT-based tracking put 60% of commercially insured people with no coverage for Zepbound as of July 2026, and only 4% with unrestricted coverage. Second, the caps mean you may not actually land on $25 if your plan’s copay is high, and the card can run out before December. Third, every government beneficiary is excluded: Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE and state assistance programs [2][3]. Both cards expire December 31, 2026.

2. The Medicare GLP-1 Bridge: $50 flat

If you are on Medicare Part D and qualify, this is the best price available to you.

From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge covers the Zepbound KwikPen for weight management at a flat $50 monthly copay [4]. Foundayo tablets and Wegovy are also covered. Single-dose Zepbound vials and single-dose pens are not, and neither is Mounjaro.

Who qualifies. All four must be true: you have Part D coverage through an eligible plan type; you are not already eligible to get a GLP-1 through your plan; you do not have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease; and you are 18 or older with a BMI of 35+, or 30+ with certain heart failure, hard-to-control hypertension or stage 3a+ chronic kidney disease, or 27+ with prediabetes, prior heart attack or stroke, or blocked arteries in the legs or arms [4].

The catch. The $50 does not count toward your Part D deductible or out-of-pocket cap, will not appear on your Explanation of Benefits, cannot be lowered by Extra Help, and cannot be spread using the Medicare Prescription Payment Plan [4]. And the program ends December 31, 2027.

Useful detail. Your prior authorization stays valid through the end of 2027 including through dose increases, as long as you stay on the same GLP-1.

3. Medicaid in a covering state: $0 to $8

Medicaid copays are nominal, so if your state covers tirzepatide for your indication, this is close to free.

Two very different rules apply:

• Required coverage. Under the Medicaid Drug Rebate Program, states must cover nearly all of a participating manufacturer’s FDA-approved drugs for medically accepted indications. That makes Mounjaro for type 2 diabetes and Zepbound for moderate-to-severe obstructive sleep apnea required benefits in every state, the latter since the December 2024 approval [5].
• Optional coverage. Weight-loss drugs are one of the few categories a state may exclude. KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Missouri, Mississippi, North Carolina, Rhode Island, Tennessee, Utah, Virginia and Wisconsin. That is down from 16 in October 2025, after California, New Hampshire, Pennsylvania and South Carolina dropped coverage [5].

The catch. Prior authorization is near universal, and several covering states have tightened. Michigan limited obesity coverage to BMI 40 or above from January 1, 2026. Rhode Island’s enacted FY2027 budget restricts coverage to type 2 diabetes from October 1, 2026. State policy changes on a quarterly formulary cycle, so verify before you rely on it.

4. Lilly self-pay for Zepbound: $299 to $449

For most cash payers, this is the answer.

Through LillyDirect, Lilly’s own direct-to-patient pharmacy channel, Zepbound self-pay is [6]:

Dose	Price per month
2.5 mg	$299
5 mg	$399
7.5 mg	$449
10 mg	$449
12.5 mg	$449
15 mg	$449

A month is 28 days: four single-dose vials, or one KwikPen. Since February 23, 2026 the vial and the KwikPen carry identical prices, so the choice between them is about how you want to inject, not what you want to pay [7].

Where you can get it. The vial is exclusive to LillyDirect, with free home delivery or free pickup at Walmart Pharmacy. The KwikPen is available through LillyDirect and, since March 16, 2026, at major pharmacies nationwide using Lilly’s KwikPen Self-Pay Savings Card, which is open to everyone including the uninsured [8]. Amazon Pharmacy separately carries it from $299 with same-day delivery to more than half of US households [9].

The catch, and it is the expensive one. The $449 price on 7.5 mg and above is a purchase offer. To keep it, you must complete each refill within 45 days of the previous delivery [10]. The ladder also excludes supplies: LillyDirect requires a needle and syringe purchase with the vial and a pen needle purchase with the KwikPen. A month of medicine is 28 days, leaving roughly 17 days of slack. Miss the window and Lilly’s current pages put the price at $499 for 7.5 mg and $699 for 10, 12.5 and 15 mg. At 10 mg, one lapse costs $250.

Other conditions. Self-pay cannot be combined with insurance on the same fill, nothing counts toward your deductible, and you may not submit the purchase for reimbursement. You must be 18 or older and a US or Puerto Rico resident.

5. Lilly self-pay for Mounjaro: $499 flat

Lilly’s LillyDirect Mounjaro page shows “Self-pay price: Starting at $499/month” on the card for every dose from 2.5 mg to 15 mg, supplied as a single-dose prefilled pen [11]. “Starting at” is Lilly’s own wording, so treat $499 as a floor, and note the page’s line that additional taxes and fees may apply. There is no vial and no dose ladder. TrumpRx.gov shows the same $499 against a $1,112.16 original price, a 55% discount [12].

Adding Mounjaro to LillyDirect at 50% to 60% off list was one of the commitments in Lilly’s November 2025 agreement with the US government.

The catch. It is $200 more per month than Zepbound at the entry dose for the same molecule. That gap is a pricing decision attached to the indication. If you have type 2 diabetes and commercial coverage, the $25 savings card tier almost always beats $499.

6. The savings card’s non-covered tier: $499

If you have commercial insurance that does not cover the drug, Lilly’s cards have a second tier.

For Zepbound, that is as low as $499 per one-month fill of the single-dose pen, with savings calculated as wholesale acquisition cost minus $499, up to 13 fills a year [2]. For Mounjaro, as low as $499 per month, with savings capped at $647 monthly and $8,411 annually [3].

The catch. For Zepbound this tier is usually the wrong answer. Ask your prescriber for the KwikPen or the vial instead and use self-pay at $299 to $449. The $499 tier exists mainly for people who need the single-dose pen presentation specifically.

7. Compounded tirzepatide: advertised $179 to $549, and narrowing

This is the route that has changed the most, and the one that requires the most care.

Compounded tirzepatide is not FDA-approved and is not a generic. It is a preparation made by a compounding pharmacy, and it has never been reviewed by the FDA for safety, effectiveness or manufacturing quality.

The legal picture. The FDA declared the tirzepatide injection shortage resolved on December 19, 2024, which closed the enforcement-discretion windows on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities [13]. On April 1, 2026 the FDA restated that tirzepatide appears on neither the 503B bulks list nor the drug shortage list, and said it does not intend to take action against a compounder that fills four or fewer prescriptions of an essentially-a-copy product in a calendar month [13]. On April 30, 2026 the agency proposed removing tirzepatide, semaglutide and liraglutide from the 503B bulks list entirely, on the grounds that there is no clinical need for compounded versions when the approved products are commercially available. The FDA has issued more than 50 warning letters to GLP-1 compounders and telehealth sellers across 2025 and 2026.

The prices. Advertised 2026 telehealth rates run roughly $179 to $549 a month, most commonly $258 to $399. Those are marketing rates from provider websites, not verified transaction data, and several providers charge more as your dose increases.

The catch. Against Lilly’s $299 starting price and $449 maintenance price, the economics that drove the compounded boom of 2024 have mostly evaporated. You are trading FDA oversight, a known supply chain and a purpose-built injector for a saving that at many providers is now under a hundred dollars a month, or zero. Add the supply uncertainty created by active enforcement and it is a worse deal than it was two years ago.

The route that is not on this list: importing from abroad

Tirzepatide is genuinely cheaper almost everywhere else, though the specific foreign figures in circulation are softer than they look. Canada’s Patented Medicine Prices Review Board caps patented drug prices, and Canadian cash prices in 2026 are reported at roughly CAD 280 to CAD 650 a month depending on dose and province, with Ontario’s formulary price reported at CAD 342 for a four-dose 2.5 mg pen. Japanese self-pay clinics advertise roughly JPY 12,500 to JPY 15,100 a month for the 2.5 mg starter. Treat both of those as third-party tracker and clinic figures rather than verified national prices: we could not confirm either against a government price file or a pharmacy’s own posted price on September 14, 2026. They are also quoted in Canadian dollars and yen and are not available to US buyers, since personal importation of prescription drugs is generally not permitted under FDA rules. Peterson-KFF put a month of Mounjaro at $1,023 in the US against $444 in the Netherlands and $319 in Japan, using June 2023 exchange rates.

Personal importation of most prescription drugs into the United States is generally not permitted under FDA rules, so this guide does not rank it as a legal route for US readers. It is context for why the US prices look the way they do, not a recommendation.

What about GoodRx, SingleCare and shopping pharmacies?

Here is the 2026 surprise: shopping pharmacies barely matters any more, because Lilly’s own price is now at the pharmacy.

GoodRx lists the Zepbound KwikPen from $299.00 without insurance at CVS, Walgreens, Walmart, Costco, Target, Sam’s Club, Amazon and the Kroger-family chains, describing that as 50% off an average retail price of about $601 for the most common version (checked September 14, 2026) [14]. That is the same number as Lilly’s self-pay starter price, because it is the same Lilly program reaching retail through a coupon rather than GoodRx beating the market. GoodRx’s own analysis puts the average monthly retail cost of Zepbound single-dose pens near $1,294, against about $605 for KwikPens and vials [14].

For the brand single-dose pens, the picture is different and much worse. SingleCare lists Zepbound from $947.00 for four 2.5 mg pens against an average retail of $1,496.80 [15]. GoodRx shows Mounjaro around $1,086 to $1,096 against an average retail near $1,348. Undiscounted retail cash prices for brand pens cluster around $1,000 to $1,350 wherever you go, with warehouse clubs at the low end.

Two rules apply to every discount card: it is used instead of insurance, never on top, and nothing you spend counts toward a deductible.

And TrumpRx?

TrumpRx.gov lists the Zepbound Vial with up to 72% off; you choose a strength and ZIP code, and at 2.5 mg that is $1,087.00 original, $788.00 savings, $299.00 final, with higher strengths following Lilly’s own ladder. Mounjaro shows $1,112.16 original, $613.16 savings, $499.00 final, 55% off [16][12]. But TrumpRx does not sell drugs. Both listings route you to LillyDirect, which checks eligibility and ships.

So TrumpRx is a price-comparison front door onto routes 4 and 5, not a cheaper eighth route. Medicare notes that TrumpRx and similar discount programs are not creditable coverage and that money spent there does not count toward Part D out-of-pocket limits.

Is there a free-drug program?

Not for tirzepatide.

The Lilly Cares Foundation provides free Lilly medicines for up to 12 months to qualifying patients, and its published medication groups as of September 14, 2026 list Cialis, Emgality, Forteo, Reyvow and Trulicity (Group 1); Basaglar, Humalog, Humulin and Lyumjev (Group 2); and immunology and oncology products (Groups 3 and 4) [17]. Neither Mounjaro nor Zepbound is on any group.

A number of widely shared pages claim otherwise. Check lillycares.com/how-to-apply before you spend time on an application.

Is a cheaper generic coming?

Not this decade, on the current record.

The core composition-of-matter patent on tirzepatide, US 9,474,780, expires May 13, 2036 on FDA’s Orange Book tables for both products. Zepbound’s listing (NDA 217806) carries further patents to June 14, 2039 and July 22, 2039; Mounjaro’s listing (NDA 215866) carries one to December 30, 2041 [18]. Tirzepatide’s New Chemical Entity exclusivity runs to May 13, 2027, and the NCE-1 date that first allowed a Paragraph IV challenge passed on May 13, 2026.

Sandoz announced FDA acceptance of its generic tirzepatide applications on June 29, 2026, and Amneal with Adalvo on July 8, 2026. Both are for the single-dose autoinjector, not the KwikPen or the vial. Acceptance for review is not approval. Approval is not permission to launch. Anyone promising cheap generic tirzepatide in the near term is guessing.

By contrast, semaglutide’s core US patent expires December 5, 2031, roughly four years earlier, which is why generic semaglutide is a 2030s story and generic tirzepatide is a late-2030s one.

The three mistakes that cost people the most

1. The wrong device on the prescription. Zepbound’s three presentations are priced and covered completely differently. The single-dose pen is the insurance presentation and the $25 card’s product. The vial and KwikPen are the self-pay products at $299 to $449. The Medicare GLP-1 Bridge covers only the KwikPen. Confirm which one your prescription names before you check out.

2. Missing the 45-day window. At 10 mg, one lapse is $250. Set a calendar reminder at day 30, not day 45.

3. Assuming your plan covers it because the drug is on the formulary. Every major PBM prints a version of the same warning: not all listed medications are covered by all plans, and the plan sponsor decides whether weight-management drugs are in the benefit at all. Call the pharmacy benefits number and ask directly before the prescription is written.

Sources

1. Eli Lilly, Zepbound savings and insurance options: https://zepbound.lilly.com/savings
2. Eli Lilly, Zepbound coverage, affordability and savings (HCP): https://zepbound.lilly.com/hcp/coverage-savings
3. Eli Lilly, Mounjaro savings and coverage: https://mounjaro.lilly.com/savings-coverage
4. CMS, Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month: https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf
5. KFF, Medicaid coverage of and spending on GLP-1s: https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
6. LillyDirect, Zepbound: https://www.lilly.com/lillydirect/zepbound
7. Eli Lilly, Zepbound now available in multi-dose KwikPen: https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management
8. Eli Lilly media statement, KwikPen self-pay pricing at major pharmacies: https://investor.lilly.com/news-releases/news-release-details/media-statement-zepbound-tirzepatide-kwikpen-now-available-self
9. Amazon Pharmacy expands access to the Zepbound KwikPen: https://www.businesswire.com/news/home/20260309587894/en/Amazon-Pharmacy-Expands-Access-to-Eli-Lillys-Zepbound-KwikPen-for-Weight-Management
10. Eli Lilly, Zepbound Self Pay Journey Program terms: https://zepbound.lilly.com/hcp/coverage-savings
11. LillyDirect, Mounjaro: https://www.lilly.com/lillydirect/mounjaro
12. TrumpRx.gov, Mounjaro: https://trumprx.gov/p/mounjaro
13. FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
14. GoodRx, Zepbound prices and coupons: https://www.goodrx.com/zepbound
15. SingleCare, Zepbound coupons and prices: https://www.singlecare.com/prescription/zepbound
16. TrumpRx.gov, Zepbound Vial: https://trumprx.gov/p/zepbound
17. Lilly Cares Foundation, how to apply and check eligibility: https://www.lillycares.com/how-to-apply
18. FDA Orange Book patent and exclusivity data for Zepbound (NDA 217806): https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=217806&Appl_type=N and Mounjaro (NDA 215866): https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=215866&Appl_type=N